secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001372514-23-000101
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals eliminates $4.75M in milestone payments to Sentrx; grants animal health license for royalty
--------------------------------------------------------------------------------

- Amendment cancels up to $4.75M in near-term milestones Kiora owed Sentrx under 2018 license.
- Kiora grants Sentrx exclusive license to KIO-201 patents for veterinary use; Kiora receives low single-digit royalty on net sales.
- Kiora retains optionality to source alternative manufacturing partners for KIO-201.
- KIO-201 is a modified hyaluronic acid for persistent corneal epithelial defects, a rare disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000101/0001372514-23-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000101/kprx-20230612.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer